Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

• Status: Completed
• Trial end date: 2019-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition Period of EP0008 [NCT01710657]

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma SA
• Collaborator: UCB Japan Co. Ltd.
• Treatments: Lacosamide

Criteria

Inclusion Criteria:

• Subject has completed the Treatment and Transition Period of EP0008 [NCT01710657]

Exclusion Criteria:

• Subjects who withdrew from EP0008 [NCT01710657]